News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TRACON Pharma (TCON) To Report Third Quarter 2016 Company Highlights And Financial Results On November 8, 2016



11/2/2016 8:41:09 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

SAN DIEGO, Nov. 01, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that it will report its third quarter 2016 financial and operating results after the close of U.S. financial markets on Tuesday, November 8, 2016. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.

Conference call and webcast:
Date:November 8, 2016
Time:4:30 pm Eastern Time (1:30 pm Pacific Time)
Dial-in:(855) 779-9066 (Domestic) or (631) 485-4859 (International)
Passcode:10003680
Via web:www.traconpharma.com; “Events and Presentation” section within the “Investors” section

A replay of the webcast will be available for 60 days on the website.

About TRACON

TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.

Company Contact: Casey Logan Chief Business Officer (858) 550-0780 ext. 236 clogan@traconpharma.com Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 Andrew@lifesciadvisors.com

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES